Survivin: An inhibitor of apoptosis in pediatric cancer

Pediatric Blood and Cancer

Volumn 47, Issue 1, 2006, Pages 4-13

  Fangusaro, Jason R ^a,b   Caldas, Hugo ^a   Jiang, Yuying ^a   Altura, Rachel A ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer; Children; Survivin; Therapy; Tumor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; EM 1421; INHIBITOR OF APOPTOSIS PROTEIN; LY 2181308; PEPTIDE FRAGMENT; REGULATOR PROTEIN; RITUXIMAB; SURVIVIN; SURVIVIN 2B [80-88]; SURVIVIN EPITOPE; UNCLASSIFIED DRUG;

ADULT DISEASE; APOPTOSIS; CANCER THERAPY; CELL DIVISION; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; KIDNEY TUMOR; LEUKEMIA; LYMPHOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA SPLICING; SOFT TISSUE TUMOR; TISSUE DIFFERENTIATION;

ADULT; APOPTOSIS; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN ISOFORMS;

EID: 33646855851     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20805     Document Type: Review

References (95)

1. Stiller CA. Epidemiology and genetics of childhood cancer. Oncogene 2004;23:6429-6444.
2. Smith CL, Dunbar PR, Mirza F, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005;113:259-266.
3. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589.
4. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004;5:897-907.
5. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002;9:459-470.
6. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
7. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656.
8. Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002;111:147-150.
9. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
10. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
11. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-410.
12. Miller LK. An exegesis of IAPs: Salvation and surprises from BIR motifs. Trends Cell Biol 1999;9:323-328.
13. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
14. Schimmer AD. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-7190.
15. Wu G, Chai J, Suber TL, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000;408:1008-1012.
16. Chantalat L, Skoufias DA, Kleman JP, et al. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 2000;6:183-189.
17. Muchmore SW, Chen J, Jakob C, et al. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell 2000;6:173-182.
18. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40:1117-1123.
19. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-5320.
20. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood 2000;96:4002-4003.
21. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004;23:39-48.
22. Shankar SL, Mani S, O'Guin KN, et al. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 2001;79:426-436.
23. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981-990.
24. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
25. Grossman D, Kim PJ, Blanc-Brude OP, et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001;108:991-999.
26. Blanc-Brude OP, Mesri M, Wall NR, et al. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003;9:2683-2692.
27. Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Cheml998;273:11177-11182.
28. Tu SP, Jiang XH, Lin MC, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003;63:7724-7732.
29. Tu SP, Cui JT, Liston P, et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005;128:361-375.
30. Lens SM, Wolthuis RM, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. Embo J 2003;22:2934-2947.
31. Skoufias DA, Mollinari C, Lacroix FB, et al. Human survivin is a kinetochore-associated passenger protein. J Cell Biol 2000;151:1575-1582.
32. Higuchi T, Uhlmann F. Cell cycle: Passenger acrobatics. Nature 2003;426:780-781.
33. Uren AG, Wong L, Pakusch M, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000;10:1319-1328.
34. Xing Z, Conway EM, Kang C, et al. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004;199:69-80.
35. Jiang Y, de Bruin A, Caldas H, et al. Essential role for survivin in early brain development. J Neurosci 2005;25:6962-6970.
36. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114:1117-1127.
37. Carvalho A, Carmena M, Sambade C, et al. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003;116:2987-2998.
38. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004;101:15100-15105.
39. Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998;351:882-883.
40. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-6102.
41. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004;314:902-907.
42. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: A novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11.
43. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005;24:1994-2007.
44. Yamada Y, Kuroiwa T, Nakagawa T, et al. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 2003;99:738-745.
45. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-216.
46. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-623.
47. Zhu N, Gu L, Findley HW, et al. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 2004;23:7545-7551.
48. Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002;9:1334-1342.
49. Konno R, Yamakawa H, Utsunomiya H, et al. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod 2000;6:529-534.
50. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonie mucosa. Hum Pathol 2001;32:119-125.
51. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
52. Altura RA, Olshefski RS, Jiang Y, et al. Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer 2003;89:1743-1749.
53. Kajiwara Y, Yamasaki F, Hama S, et al. Expression of survivin in astrocytic tumors: Correlation with malignant grade and prognosis. Cancer 2003;97:1077-1083.
54. Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ, et al. Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch Pathol Lab Med 2003;127:826-833.
55. Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004;50:1986-1993.
56. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004;100:751-757.
57. Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: First clues to a role of survivin-2B in tumour progression. Br J Cancer 2002;86:737-743.
58. Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-3257.
59. Jiang Y, Saavedra HI, Holloway MP, et al. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 2004;279:40511-40520.
60. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-240.
61. Yamasaki L. Role of the RB tumor suppressor in cancer. Cancer Treat Res 2003;115:209-239.
62. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-1542.
63. Kawakami H, Tomita M, Matsuda T, et al. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 2005;115:967-974.
64. Sasaki T, Lopes MB, Hankins GR, et al. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol (Berl) 2002;104:105-109.
65. Katoh M, Wilmotte R, Belkouch MC, et al. Survivin in brain tumors: An attractive target for immunotherapy. J Neurooncol 2003;64:71-76.
66. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-1068.
67. Chakravarti A, Zhai GG, Zhang M, et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004;23:7494-7506.
68. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: Biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005;92:359-365.
69. Bodey B, Bodey V, Siegel SE, et al. Survivin expression in childhood medulloblastomas: A possible diagnostic and prognostic marker. In Vivo 2004;18:713-718.
70. Kappler M, Taubert H, Bartel F, et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 2005;13:167-172.
71. Taubert H, Kappler M, Bache M, et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 2005;24:5258-5261.
72. Caldas H, Holloway MP, Hall BM, et al. Survivin-directed RNA interference cocktail is a potent suppressor of tumor growth in vivo. J Med Genet 2006;43:119-128.
73. Trieb K, Lehner R, Stulnig T, et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003;29:379-382.
74. Miller MA, Karacay B, Breslow NE, et al. Prognostic value of quantifying apoptosis factor expression in favorable histology wilms tumors. J Pediatr Hematol Oncol 2005;27:11-14.
75. Takamizawa S, Scott D, Wen J, et al. The survivin:fas ratio in pediatriec renal tumors. J Pediatr Surg 2001;36:37-42.
76. Pritchard J, Hickman JA. Why does stage 4s neuroblastoma regress spontaneously? Lancet 1994;344:869-870.
77. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995;24:215-221.
78. Plantaz D, Mohapatra G, Matthay KK, et al. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 1997;150:81-89.
79. Bown N. Neuroblastoma tumour genetics: Clinical and biological aspects. J Clin Pathol 2001;54:897-910.
80. Spitz R, Hero B, Ernestus K, et al. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res 2003;9:4835-4840.
81. Ito R, Asami S, Motohashi S, et al. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 2005;28:565-568.
82. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000;111:196-203.
83. Carter BZ, Kornblau SM, Tsao T, et al. Caspase-independent cell death in AML: Caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003;102:4179-4186.
84. Nakagawa Y, Yamaguchi S, Hasegawa M, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 2004;28:487-494.
85. Invernizzi R, Travaglino E, Lunghi M, et al. Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma 2004;45:2229-2237.
86. Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004;10:3737-3744.
87. Paydas S, Tanriverdi K, Yavuz S, et al. Survivin and aven: Two distinct antiapoptotic signals in acute leukemias. Ann Oncol 2003;14:1045-1050.
88. Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: A novel biomarker in practical hemato-oncology. Leuk Lymphoma 2002;43:2249-2255.
89. Zhou M, Gu L, Li F, et al. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002;303:124-131.
90. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-1925.
91. Siegel S, Wagner A, Schmitz N, et al. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 2003;122:911-914.
92. Ansell SM, Arendt BK, Grote DM, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004;18:616-623.
93. Ma H, Nguyen C, Lee KS, et al. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005;24:3619-3631.
94. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19.
95. Kappler M, Kohler T, Kampf C, et al. Increased survivin transcript levels: An independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 2001;95:360-363.